11:12 AM EST, 11/04/2024 (MT Newswires) -- Alvotech ( ALVO ) and Advanz Pharma said Monday that the European Medicines Agency accepted the marketing authorization application for AVT05 to treat several chronic inflammatory diseases.

AVT05 is a biosimilar of Simponi and Simponi Aria, or golimumab, which are marketed by Johnson & Johnson's ( JNJ ) Janssen Biotech unit.

The approvals process is projected to close in Q4 2025, according to the companies.

Price: 13.00, Change: -0.02, Percent Change: -0.15